<DOC>
	<DOCNO>NCT01480609</DOCNO>
	<brief_summary>This open-label , single dose , fix sequence , two treatment period study enrol 8 patient ( obtain 6 evaluable ) end stage renal disease ( ESRD ) receive haemodialysis . Patients remain unit treatment period admission collection final PK sample . The dos ezogabine/retigabine two treatment period separate least 7 day .</brief_summary>
	<brief_title>Effect Haemodialysis Pharmacokinetics Ezogabine/Retigabine Its N-acetyl Metabolite</brief_title>
	<detailed_description>Treatment Period 1 : Subjects admit Day -1 baseline assessment perform . On Day 1 subject receive single dose 100mg ezogabine/retigabine immediate release ( IR ) dialysis start 4 hour post-dose . Pharmacokinetic ( PK ) sample collect approximately 68 hour post-dose . Samples dialysate collect 0-1 , 1-2 , 2-3 , 3-4 hour ( available ) aliquot , time start dialysis . The volume dialysate collect aliquot record . Four sample predialyzer ( `` arterial '' line ) blood four sample postdialyzer ( `` venous '' line ) blood obtain haemodialysis procedure approximately one hour interval start immediately prior start procedure finish end procedure . Subjects discharge unit follow collection last PK sample . Treatment Period 2 : Subjects admit Day -1 baseline assessment perform . On Day 1 follow completion schedule dialysis session subject receive single dose 100mg ezogabine/retigabine IR . PK sample collect approximately 68 hour post-dose . Subjects discharge unit follow collection last PK sample . In treatment period , PK blood sample obtain pre-dose , 0.5 , 1 , 1.5 , 2 , 2.5 , 3 , 4 , 5 , 6 , 7 , 8 , 12 , 16 , 24 , 36 , 48 , 60 68 hour ( prior next dialysis session - whichever sooner ) post-dose . Subjects discharge final post-dose draw .</detailed_description>
	<mesh_term>Ezogabine</mesh_term>
	<criteria>Male female 18 year old , time signing informed consent . ESRD patient minimal residual renal function receive stabilise haemodialysis regimen . Body mass index range 1842 kg/m2 screen . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one contraception method list . Childbearing potential agrees use one contraception method list . Female subject must agree use contraception least 1 week postlast dose . Male subject female partner childbearing potential must agree use one contraception method list . This criterion must follow time first dose study medication least 1 week postlast dose . Capable give write informed consent , include compliance requirement restriction list consent form . Subjects fluctuate rapidly deteriorate condition adequately control medication Subjects sign clinically significant infection . Has active suicidal plan/intent active suicidal thought past 6 month . Has history suicide attempt last 2 year 1 lifetime suicide attempt . Subjects medical condition , judgement investigator medical monitor , could jeopardize integrity data derive subject safety subject Clinically relevant laboratory physical examination abnormality ( except renal function test deviation clinical laboratory value relate renal impairment ) . Subjects blood pressure , rest â‰¥ 3 minute , high 160/95 mmHg low 100/50 mmHg . The patient receive anthihypertensive treatment need stabilise treatment three month . The screen ECGs measurement must within limit indicate protocol . Any significant arrhythmia , opinion principal investigator GSK medical monitor , interfere safety individual subject . History hemoglobinopathy . A radiological test involve contrast dye within 4 week prior screen . Poor peripheral venous access . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . A positive prestudy drug/alcohol screen . A positive test HIV antibody . History regular alcohol consumption within 6 month study . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Pregnant female Lactating female . Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>